Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway
BW Higgs, Z Liu, B White, W Zhu, WI White… - Annals of the rheumatic …, 2011 - Elsevier
Objective To characterise activation of the type I interferon (IFN) pathway in patients with
systemic lupus erythematosus (SLE), dermatomyositis (DM), polymyositis (PM), rheumatoid
arthritis (RA) and systemic scleroderma (SSc) and to evaluate the potential to develop a
molecular diagnostic tool from the peripheral blood that reflects this activation in disease-
affected tissues. Methods Overexpressed transcripts were identified in the whole blood (WB)
of 262 patients with SLE, 44 with DM, 33 with PM, 28 with SSc and 89 with RA and …
systemic lupus erythematosus (SLE), dermatomyositis (DM), polymyositis (PM), rheumatoid
arthritis (RA) and systemic scleroderma (SSc) and to evaluate the potential to develop a
molecular diagnostic tool from the peripheral blood that reflects this activation in disease-
affected tissues. Methods Overexpressed transcripts were identified in the whole blood (WB)
of 262 patients with SLE, 44 with DM, 33 with PM, 28 with SSc and 89 with RA and …
